Rift Valley fever

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Rift Valley fever
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	Fever, muscle pain, headache, dizziness, weight loss, liver abnormalities
Complications	Hemorrhagic fever, encephalitis, retinitis, blindness
Onset	2–6 days after exposure
Duration	Typically 4–7 days
Types	N/A
Causes	Rift Valley fever virus
Risks	Contact with infected animals or their products, mosquito bites
Diagnosis	Serology, PCR
Differential diagnosis	N/A
Prevention	Vaccination, avoiding contact with infected animals, mosquito control
Treatment	Supportive care
Medication	N/A
Prognosis	Generally good, but can be severe in some cases
Frequency	Occurs in Africa and the Middle East
Deaths	N/A

Viruses illustration

Rift Valley fever distribution

Rift Valley Fever (RVF) is a viral zoonosis that primarily affects animals but also has the capacity to infect humans. The disease is caused by the Rift Valley fever virus (RVFV), a member of the genus Phlebovirus in the family Phenuiviridae. It was first identified in 1931 during an investigation into an epidemic among sheep on a farm in the Rift Valley of Kenya. Since then, outbreaks have been reported in sub-Saharan Africa, with some cases occurring in the Arabian Peninsula.

Etiology

RVFV is transmitted by mosquitoes, notably those in the genus Aedes and Culex. The virus can also be transmitted through contact with the blood, body fluids, or tissues of infected animals. In humans, RVFV infection can result in a range of clinical manifestations, from mild flu-like symptoms to severe conditions such as hemorrhagic fever, encephalitis, or ocular disease.

Epidemiology

The distribution of RVF is closely tied to the ecology of its mosquito vectors, with outbreaks often occurring after periods of heavy rainfall, which facilitate mosquito breeding. RVF is endemic in many African countries and parts of the Middle East. The movement of animals and global climate change are factors that could potentially expand the range of RVFV.

Clinical Manifestations

In humans, the incubation period of RVFV ranges from 2 to 6 days, following which infected individuals may develop a range of symptoms. Most infections are mild, but approximately 1-2% of cases progress to more severe forms of the disease. Symptoms of RVF include fever, weakness, back pain, dizziness, and weight loss. Severe cases may lead to hemorrhagic fever, encephalitis, or ocular disease, which can result in permanent vision loss.

Diagnosis

Diagnosis of RVF is primarily based on the detection of viral RNA, antibodies against the virus, or the virus itself in blood samples. Techniques such as reverse transcription polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), and virus isolation can be used.

Prevention and Control

Preventive measures against RVF include controlling mosquito populations and vaccinating animals in endemic areas. Personal protective measures, such as using insect repellent and wearing protective clothing, can also reduce the risk of infection. Public health efforts focus on surveillance, education, and outbreak response to mitigate the impact of the disease.

Treatment

There is no specific antiviral treatment for RVF. Management of the disease is supportive and based on the symptoms presented by the patient. In cases of severe infection, hospitalization may be required for intensive care.

Summary

Rift Valley Fever remains a significant public health concern in endemic regions, with potential for global spread. Ongoing research into vaccines and antiviral therapies, along with effective vector control and surveillance programs, are crucial in managing and preventing RVF outbreaks.